Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin for Preventing Graves' Ophthalmopathy in Newly Diagnosed Graves' Disease
NCT07883356Phase 2Not yet recruiting
- Sponsor
- Region Skåne
- Start
- Nov 2026
- Primary completion
- Nov 2032
- Countries
- 1
01
Overview
A Phase 2 trial of atorvastatin in Graves Orbitopathy (GO), sponsored by Region Skåne. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
atorvastatin
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on NCT07883356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07883356.